Details checkedClinical trial listing onlyCheckedregistry

AP-HP SERORL aspirin and folic acid SSNHL study

Also known as: Aspirin + Acid Folic, SERORL, APHP230836, 2024-513710-35

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 3

Status

Active

Target Gene

—

Route / Mode

Oral tablets plus standard steroid care

Confidence

82%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

France

Population

adult, sudden, sensorineural, ssnhl

Trial IDs

Mechanism

Adjunctive aspirin 100 mg/day plus folic acid 5 mg/day, added to standard corticosteroid care, being evaluated for sudden sensorineural hearing loss based on a microvascular/homocysteine hypothesis.

Indications

Hearing Loss Sudden Hearing Loss Sensorineural Hearing Loss

Notes

Corrected from a hospital-as-company row. ClinicalTrials.gov lists AP-HP as the non-industry lead sponsor. The study is a Phase 3 randomized trial that is not yet recruiting as of the January 2026 registry update, so it should be visible as an active institution-led trial, not an industry program.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...

IDs: NCT07113158, SERORL, APHP230836, 2024-513710-35

Open

Key Events

2025-08-08

SERORL Phase 3 aspirin/folic acid SSNHL study first posted

2026-01-14

ClinicalTrials.gov update listed SERORL as not yet recruiting

Clinical Trials (1)